复发或残留垂体腺瘤伽玛刀放射外科治疗后的长期肿瘤控制:一项基于人群的队列研究
该研究为基于人群的观察性队列研究,纳入1999年至2020年间因术后残留或复发垂体腺瘤接受伽玛刀放射外科治疗的患者147例,中位随访8.1年。5年和10年无进展生存率分别为86%和68%,中位无进展生存期为18.7年;生长激素腺瘤在回归分析中肿瘤进展风险显著较低(OR 0.11,p=0.003)。垂体功能减退是最常见的不良放射事件,影响32%的患者。
要点
- 伽玛刀治疗后5年和10年无进展生存率分别为86%和68%,中位无进展生存期18.7年
- 生长激素腺瘤肿瘤进展风险显著较低(OR 0.11,p=0.003)
- 垂体功能减退最常见不良放射事件,发生率为32%
核心结论
- 伽玛刀放射外科是复发或残留垂体腺瘤的有效治疗选择,可提供显著的长期肿瘤控制。
- 不良放射事件特别是垂体功能减退的风险不可忽视。
研究设计与样本
- 基于人群的观察性队列研究,纳入1999年至2020年间因术后残留或复发垂体腺瘤接受伽玛刀放射外科治疗的患者147例,中位随访8.1年。
主要发现
- 伽玛刀治疗后5年和10年无进展生存率分别为86%和68%,中位无进展生存期为18.7年。
- 回归分析中,生长激素腺瘤肿瘤进展风险显著较低(OR 0.11,p=0.003)。
- 垂体功能减退是最常见的不良放射事件,影响32%的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pituitary adenomas (PAs) often require adjuvant Gamma Knife radiosurgery (GKRS) due to partial resection or postoperative recurrence. The purpose of this study was to evaluate the long-term efficacy of GKRS for such cases. METHODS: Population-based, observational cohort study of patients who underwent GKRS for postoperative residual or recurrent PAs between 1999 and 2020. We assessed long-term progression-free survival (PFS), identified predictors of tumor growth, and documented adverse radiation events (AREs). RESULTS: 147 patients were included, with a median follow-up time of 8.1 years. Following GKRS, the 5-year and 10-year PFS was 86% and 68%, respectively, with a median PFS of 18.7 years. Somatotrophic adenomas showed a significantly lower risk of tumor progression in the regression analysis (OR 0.11, p = 0.003). Hypopituitarism was the most common ARE, affecting 32% of patients. CONCLUSION: GKRS is an effective treatment option for recurrent or residual PAs, offering substantial long-term control. However, the risk for AREs, particularly hypopituitarism, is not negligeable.
引用
- Gabri A, Lindberg F, Kristiansson H, et al. Long-term tumor control following gamma-knife radiosurgery of recurrent or residual pituitary adenomas: a population-based cohort study. Acta Neurochir (Wien). 2024. PMID: 39613987. doi:10.1007/s00701-024-06380-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。